5/15/2018 1:03:17 PM - This Irish firm from the Medical - Ethical Drugs industry group reported earnings +8% on +5% sales revenues for the Mar &#39;18 quarter, and prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria). Fundamental concerns remain.<br><hr>7/23/2015 12:58:00 PM - Challenging its 52-week high with today&#39;s 2nd consecutive volume-driven gain. Reported earnings -1% on +4% sales revenues for the Jun &#39;15 quarter. Noted with caution in the 7/16/15 mid-day report - <em>&quot;This Irish firm from the Medical - Ethical Drugs industry group reported earnings <strong>+20%</strong> on <strong>+11%</strong> sales revenues for the Mar &#39;15 quarter, and prior quarterly comparisons were below the <strong>+25%</strong> minimum earnings guideline (<strong>C</strong> criteria). Fundamental concerns remain, although it has earned high ranks.&quot;  </em><br><hr>7/22/2015 1:07:31 PM - Holding its ground perched near its 52-week high since noted with caution in the 7/16/15 mid-day report - <em>&quot;This Irish firm from the Medical - Ethical Drugs industry group reported earnings <strong>+20%</strong> on <strong>+11%</strong> sales revenues for the Mar &#39;15 quarter, and prior quarterly comparisons were below the <strong>+25%</strong> minimum earnings guideline (<strong>C</strong> criteria). Fundamental concerns remain, although it has earned high ranks.&quot;  </em><br><hr>7/16/2015 12:51:09 PM - This Irish firm from the Medical - Ethical Drugs industry group reported earnings <strong>+20%</strong> on <strong>+11%</strong> sales revenues for the Mar &#39;15 quarter, and prior quarterly comparisons were below the <strong>+25%</strong> minimum earnings guideline (<strong>C</strong> criteria). Fundamental concerns remain, although it has earned high ranks.<br><hr>5/6/2015 1:13:43 PM - Reported earnings <strong>+20%</strong> on <strong>+11%</strong> sales revenues for the Mar &#39;15 quarter. This Irish firm from the Medical - Ethical Drugs industry group was last noted in the 4/10/15 mid-day report - <em>&quot;Recently found support at its 200 DMA line. Reported earnings <strong>+16%</strong> on <strong>+19%</strong> for the Dec &#39;14 quarter, below the <strong>+25%</strong> minimum earnings guideline (<strong>C</strong> criteria). Fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>4/10/2015 12:48:28 PM - This Irish firm from the Medical - Ethical Drugs industry group was noted in prior mid-day reports - <em>&quot;Recently found support at its 200 DMA line. Reported earnings <strong>+16%</strong> on <strong>+19%</strong> for the Dec &#39;14 quarter, below the <strong>+25%</strong> minimum earnings guideline (<strong>C</strong> criteria). Fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>4/9/2015 1:07:09 PM - Recently found support at its 200 DMA line. Reported earnings <strong>+16%</strong> on <strong>+19%</strong> for the Dec &#39;14 quarter, below the <strong>+25%</strong> minimum earnings guideline (<strong>C</strong> criteria). This Irish firm from the Medical - Ethical Drugs industry group was noted in prior mid-day reports - <em>&quot;Fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>4/8/2015 1:10:41 PM - Gapped up today, and it recently tested support at its 200 DMA line. Reported earnings <strong>+16%</strong> on <strong>+19%</strong> for the Dec &#39;14 quarter. This Irish firm from the Medical - Ethical Drugs industry group was noted in prior mid-day reports - <em>&quot;Fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>10/3/2014 12:16:12 PM - Gapped up today. Hovering near its 52-week high, it recently tested support at its 50 DMA line while consolidating since AbbVie Inc&#39;s (ABBV) takeover bid. Reported earnings <strong>+42%</strong> on <strong>+20%</strong> for the Jun &#39;14 quarter. This Irish firm from the Medical - Ethical Drugs industry group was noted in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>9/26/2014 12:31:49 PM - Hitting a new 52-week high today. Tested support at its 50 DMA line while consolidating since AbbVie Inc&#39;s (ABBV) takeover bid. Reported earnings <strong>+42%</strong> on <strong>+20%</strong> for the Jun &#39;14 quarter. This Irish firm from the Medical - Ethical Drugs industry group was noted in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>9/23/2014 12:26:39 PM - Pulling back from its 52-week high with higher volume behind today&#39;s <strong>3</strong>rd consecutive loss while testing support at its 50 DMA line. Held its ground above its 50 DMA line while consolidating since AbbVie Inc&#39;s (ABBV) takeover bid. Reported earnings <strong>+42%</strong> on <strong>+20%</strong> for the Jun &#39;14 quarter. This Irish firm from the Medical - Ethical Drugs industry group was noted in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>8/7/2014 12:41:27 PM - Gapped down on the prior session, retreating from its 52-week high where it has been hovering since AbbVie Inc&#39;s (ABBV) takeover bid. Reported earnings <strong>+42%</strong> on <strong>+20%</strong> for the Jun &#39;14 quarter. This Irish firm from the Medical - Ethical Drugs industry group tallied an impressive spurt of big volume-driven gains in recent weeks yet it was noted with caution repeatedly in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>8/6/2014 12:47:14 PM - Gapped down today, retreating from its 52-week high where it has been hovering since AbbVie Inc&#39;s (ABBV) takeover bid. Reported earnings <strong>+42%</strong> on <strong>+20%</strong> for the Jun &#39;14 quarter. This Irish firm from the Medical - Ethical Drugs industry group tallied an impressive spurt of big volume-driven gains in recent weeks yet it was noted with caution repeatedly in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>7/30/2014 12:55:54 PM - Perched at its 52-week high since AbbVie&#39;s takeover bid. Reported earnings <strong>+42%</strong> on <strong>+20%</strong> for the Jun &#39;14 quarter. This Irish firm from the Medical - Ethical Drugs industry group tallied an impressive spurt of big volume-driven gains in recent weeks yet it was noted with caution repeatedly in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>7/24/2014 1:03:27 PM - Perched at its 52-week high today after AbbVie&#39;s higher takeover bid. Reported earnings <strong>+42%</strong> on <strong>+20%</strong> for the Jun &#39;14 quarter. This Irish firm from the Medical - Ethical Drugs industry group tallied an impressive spurt of big volume-driven gains in recent weeks yet it was noted with caution repeatedly in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>7/23/2014 1:04:24 PM - Perched at its 52-week high today after AbbVie&#39;s higher takeover bid. This Irish firm from the Medical - Ethical Drugs industry group tallied an impressive spurt of big volume-driven gains in recent weeks yet it was noted with caution repeatedly in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>7/22/2014 12:40:06 PM - Perched at its 52-week high today after AbbVie&#39;s higher takeover bid. This Irish firm from the Medical - Ethical Drugs industry group tallied an impressive spurt of big volume-driven gains in recent weeks yet it was noted with caution repeatedly in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>7/21/2014 12:28:59 PM - Perched at its 52-week high today after AbbVie&#39;s higher takeover bid. This Irish firm from the Medical - Ethical Drugs industry group tallied an impressive spurt of big volume-driven gains in recent weeks yet it was noted with caution repeatedly in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>7/18/2014 12:31:34 PM - Perched at its 52-week high today adding to a streak of gains backed by above average volume. Stubbornly held its ground and rallied after rejecting AbbVie&#39;s <strong>$46</strong> Billion inversion takeover bid. This Irish firm from the Medical - Ethical Drugs industry group tallied an impressive spurt of big volume-driven gains in recent weeks yet it was noted with caution repeatedly in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>7/17/2014 12:46:37 PM - Consolidating near its 52-week high, enduring distributional pressure this week following a streak of gains backed by above average volume. Stubbornly held its ground and rallied after rejecting AbbVie&#39;s <strong>$46</strong> Billion inversion takeover bid. This Irish firm from the Medical - Ethical Drugs industry group tallied an impressive spurt of big volume-driven gains in recent weeks yet it was noted with caution repeatedly in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>7/16/2014 12:40:11 PM - Consolidating near its 52-week high following a streak of <strong>4</strong> consecutive gains backed by above average volume. Stubbornly held its ground and rallied after rejecting AbbVie&#39;s <strong>$46</strong> Billion inversion takeover bid. This Irish firm from the Medical - Ethical Drugs industry group tallied an impressive spurt of big volume-driven gains in recent weeks yet it was noted with caution repeatedly in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>7/15/2014 1:03:09 PM - Perched near its 52-week high today following <strong>4</strong> consecutive gains backed by above average volume. Stubbornly held its ground and rallied after rejecting AbbVie&#39;s <strong>$46</strong> Billion inversion takeover bid. This Irish firm from the Medical - Ethical Drugs industry group tallied an impressive spurt of big volume-driven gains in recent weeks yet it was noted with caution repeatedly in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>7/14/2014 12:39:48 PM - Hitting another new 52-week high with today&#39;s <strong>4</strong>th consecutive gain backed by above average volume. Stubbornly held its ground and rallied after rejecting AbbVie&#39;s <strong>$46</strong> Billion inversion takeover bid. This Irish firm from the Medical - Ethical Drugs industry group tallied an impressive spurt of big volume-driven gains in recent weeks yet it was noted with caution repeatedly in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>7/11/2014 12:25:45 PM - Hitting a new 52-week high with today&#39;s <strong>3</strong>rd consecutive gain backed by above average volume. Stubbornly held its ground and rallied after rejecting AbbVie&#39;s <strong>$46</strong> Billion inversion takeover bid. This Irish firm from the Medical - Ethical Drugs industry group tallied an impressive spurt of big volume-driven gains in recent weeks yet it was noted with caution repeatedly in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>7/10/2014 12:34:18 PM - Stubbornly held its ground and rallied after rejecting AbbVie&#39;s <strong>$46</strong> Billion inversion takeover bid. This Irish firm from the Medical - Ethical Drugs industry group tallied an impressive spurt of big volume-driven gains in recent weeks yet it was noted with caution repeatedly in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>7/8/2014 1:08:04 PM - Pulling back today with higher volume. Stubbornly held its ground and rallied after rejecting AbbVie&#39;s <strong>$46</strong> Billion inversion takeover bid. This Irish firm from the Medical - Ethical Drugs industry group tallied an impressive spurt of big volume-driven gains in recent weeks yet it was noted with caution repeatedly in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>6/27/2014 1:13:23 PM - After rejecting AbbVie&#39;s <strong>$46</strong> Billion inversion takeover bid this Irish firm from the Medical - Ethical Drugs industry group gapped up for a new 52-week high on 6/20/14. Its considerable volume-driven gain was among an impressive spurt of big volume-driven gains in recent weeks. Noted repeatedly in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>6/25/2014 12:34:55 PM - After rejecting AbbVie&#39;s <strong>$46</strong> Billion inversion takeover bid this Irish firm from the Medical - Ethical Drugs industry group gapped up for a new 52-week high on 6/20/14. Its considerable volume-driven gain was among an impressive spurt of <strong>4</strong> big volume-driven gains in the span of <strong>6</strong> sessions. Noted repeatedly in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>6/24/2014 12:34:46 PM - After rejecting AbbVie&#39;s <strong>$46</strong> Billion inversion takeover bid this Irish firm from the Medical - Ethical Drugs industry group gapped up for a new 52-week high on 6/20/14. Its considerable volume-driven gain was among an impressive spurt of <strong>4</strong> big volume-driven gains in the span of <strong>6</strong> sessions. Noted repeatedly in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>6/23/2014 12:36:08 PM - After rejecting AbbVie&#39;s <strong>$46</strong> Billion inversion takeover bid this Irish firm from the Medical - Ethical Drugs industry group gapped up for a new 52-week high on the prior session. Its considerable volume-driven gain added to an impressive spurt of <strong>3</strong> big volume-driven gains in the span of <strong>5</strong> sessions. Noted in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>6/20/2014 1:11:14 PM - After rejecting AbbVie&#39;s <strong>$46</strong> Billion inversion takeover bid this Irish firm from the Medical - Ethical Drugs industry group gapped up for a new 52-week high. Today&#39;s considerable volume-driven gain adds to an impressive spurt of <strong>3</strong> big volume-driven gains in the span of <strong>5</strong> sessions. Noted in prior mid-day reports - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>6/18/2014 12:26:30 PM - Irish firm from the Medical - Ethical Drugs industry group is hitting another new 52-week high with today&#39;s <strong>2</strong>nd considerable volume-driven gain in the span of <strong>3</strong> sessions. Held its ground stubbornly and wedged higher with all other gains on the small side and lacking great volume conviction since noted with caution in the 5/07/14 mid-day report - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>6/17/2014 12:36:24 PM - Irish firm from the Medical - Ethical Drugs industry group hit a new 52-week high on the prior session with a considerable volume-driven gain. Held its ground stubbornly and wedged higher with all other gains on the small side and lacking great volume conviction since last noted with caution in the 5/07/14 mid-day report - <em>&quot;Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>5/7/2014 12:31:56 PM - Irish firm from the Medical - Ethical Drugs industry group had a &quot;negative reversal after hitting a new 52-week high when last noted in the 5/02/14 mid-day report - <em>&quot;Rebounded from below its 50 DMA line with a recent streak of volume-driven gains. Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain. It has earned high ranks, however it was previously noted - &#39;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>5/2/2014 12:36:30 PM - Irish firm from the Medical - Ethical Drugs industry group hit another new 52-week high today then reversed into the red. Rebounded from below its 50 DMA line with a recent streak of volume-driven gains. Reported earnings <strong>+41%</strong> on <strong>+18%</strong> sales for the Mar &#39;14 quarter, its <strong>2</strong>nd consecutive quarterly comparison with earnings above the <strong>+25%</strong> minimum guideline (<strong>C</strong> criteria) but fundamental concerns remain.  It has earned high ranks, however it was previously noted - <em>&quot;Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&quot;</em><br><hr>4/30/2014 12:19:59 PM - Perched near its 52-week high today following considerable gains marked by volume. Rebounded from below its 50 DMA line with a streak of volume-driven gains last week, however, it was noted with caution in prior mid-day reports - <em>&quot;Reported earnings <strong>+36%</strong> on <strong>+12%</strong> sales for the Dec &#39;13 quarter, but fundamental concerns remain. Noted in several February mid-day reports - &#39;Irish firm from the Medical - Ethical Drugs industry group is perched at all-time highs. Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>4/29/2014 12:24:16 PM - Gapped down today after hitting a new 52-week high on the prior session with a considerable gain marked by volume. Rebounded from below its 50 DMA line with a streak of volume-driven gains last week, however, it was noted with caution in prior mid-day reports - <em>&quot;Reported earnings <strong>+36%</strong> on <strong>+12%</strong> sales for the Dec &#39;13 quarter, but fundamental concerns remain. Noted in several February mid-day reports - &#39;Irish firm from the Medical - Ethical Drugs industry group is perched at all-time highs. Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>4/28/2014 12:08:59 PM - Perched within striking distance of its 52-week high today following a recent streak of gains marked by volume during which it rebounded from below its 50 DMA line. Noted with caution in prior mid-day reports - <em>&quot;Reported earnings <strong>+36%</strong> on <strong>+12%</strong> sales for the Dec &#39;13 quarter, but fundamental concerns remain. Noted in several February mid-day reports - &#39;Irish firm from the Medical - Ethical Drugs industry group is perched at all-time highs. Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>4/24/2014 1:02:41 PM - Approaching its 52-week high today while on track for an <strong>8</strong>th consecutive gain. Rebounded from below its 50 DMA line with considerable volume-driven gains. Noted with caution in prior mid-day reports - <em>&quot;Reported earnings <strong>+36%</strong> on <strong>+12%</strong> sales for the Dec &#39;13 quarter, but fundamental concerns remain. Noted in several February mid-day reports - &#39;Irish firm from the Medical - Ethical Drugs industry group is perched at all-time highs. Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>4/23/2014 1:12:22 PM - Gapped up on the prior session, rebounding above its 50 DMA line with a volume-driven gain. Noted with caution in the 3/28/14 mid-day report - <em>&quot;Reported earnings <strong>+36%</strong> on <strong>+12%</strong> sales for the Dec &#39;13 quarter, but fundamental concerns remain. Noted in several February mid-day reports - &#39;Irish firm from the Medical - Ethical Drugs industry group is perched at all-time highs. Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>4/22/2014 12:48:08 PM - Gapped up today rebounding above its 50 DMA line with a volume-driven gain. Last noted with caution in the 3/28/14 mid-day report - <em>&quot;Reported earnings <strong>+36%</strong> on <strong>+12%</strong> sales for the Dec &#39;13 quarter, but fundamental concerns remain. Noted in several February mid-day reports - &#39;Irish firm from the Medical - Ethical Drugs industry group is perched at all-time highs. Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&#39;&quot; </em><br><hr>3/28/2014 12:46:20 PM - Sputtering below its 50 DMA line since last noted with caution in the 3/20/14 mid-day report, enduring distributional pressure. Reported earnings <strong>+36%</strong> on <strong>+12%</strong> sales for the Dec &#39;13 quarter, but fundamental concerns remain. Noted in several February mid-day reports - <em>&quot;Irish firm from the Medical - Ethical Drugs industry group is perched at all-time highs. Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&quot; </em><br><hr>3/20/2014 12:55:31 PM - Consolidating near its 50 DMA line, an important support level. Endured recent distributional pressure. Reported earnings <strong>+36%</strong> on <strong>+12%</strong> sales for the Dec &#39;13 quarter, but fundamental concerns remain. Made gradual progress after noted in several February mid-day reports with caution - <em>&quot;Irish firm from the Medical - Ethical Drugs industry group is perched at all-time highs. Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&quot; </em><br><hr>3/7/2014 1:11:48 PM - Retreating from its 52-week high, enduring recent distributional pressure. Reported earnings <strong>+36%</strong> on <strong>+12%</strong> sales for the Dec &#39;13 quarter, but fundamental concerns remain. Made gradual progress after noted in several February mid-day reports with caution - <em>&quot;Irish firm from the Medical - Ethical Drugs industry group is perched at all-time highs. Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&quot; </em><br><hr>3/6/2014 1:01:08 PM - Hovering near its 52-week high. Held its ground and rose steadily since noted in several February mid-day reports with caution - <em>&quot;Irish firm from the Medical - Ethical Drugs industry group is perched at all-time highs. Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&quot; </em><br><hr>3/4/2014 12:43:07 PM - Stubbornly held its ground and rose steadily since noted in several February mid-day reports with caution - <em>&quot;Irish firm from the Medical - Ethical Drugs industry group is perched at all-time highs. Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&quot; </em><br><hr>2/28/2014 12:59:20 PM - Pulling back today with high volume. Stubbornly held its ground and rose steadily since noted in recent mid-day reports with caution - <em>&quot;Irish firm from the Medical - Ethical Drugs industry group is perched at all-time highs. Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&quot; </em><br><hr>2/14/2014 12:28:39 PM - Stubbornly holding its ground and rising steadily since noted in recent mid-day reports with caution - <em>&quot;Irish firm from the Medical - Ethical Drugs industry group is perched at all-time highs. Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&quot; </em><br><hr>2/13/2014 1:04:19 PM - Stubbornly holding its ground and rising since noted in recent mid-day reports with caution - <em>&quot;Irish firm from the Medical - Ethical Drugs industry group is perched at all-time highs. Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&quot; </em><br><hr>2/12/2014 12:51:19 PM - Stubbornly holding its ground and rising since last noted in the 2/07/14 mid-day report with caution - <em>&quot;Irish firm from the Medical - Ethical Drugs industry group is perched at all-time highs. Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).&quot; </em><br><hr>2/7/2014 12:45:23 PM - Irish firm from the Medical - Ethical Drugs industry group is perched at all-time highs. Earnings history is not a match with the fact-based investment system&#39;s guidelines (<strong>C</strong> and <strong>A</strong> criteria).<br><hr>